<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37018291</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients.</ArticleTitle><Pagination><StartPage>e0283983</StartPage><MedlinePgn>e0283983</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0283983</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0283983</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cytokines induced by SARS-CoV-2 infection play a crucial role in the pathophysiology of COVID-19 and hyperinflammatory responses have been associated with poor clinical outcomes, with progression to severe conditions or long-term subacute complications named as long-COVID-19.</AbstractText><AbstractText Label="METHODS">In this cross-sectional study, we aimed to evaluate a set of antigen-specific inflammatory cytokines in blood from recovered COVID-19 individuals or who suffered a post-acute phase of SARS-CoV-2 infection compared to healthy individuals with no history of COVID-19 exposition or infection. Interferon-gamma (IFN-&#x3b3;), IFN-&#x3b3;-induced protein 10 (IP-10), tumor necrosis factor (TNF), IL-1&#x3b2;, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, and IL-17A were quantified by multiplex cytometric bead assay and enzyme-linked immunosorbent assay after stimulation of whole blood with recombinant Spike protein from SARS-CoV-2. Additionally, all participants have evaluated for anti-(S) protein-specific IgG antibodies. Clinical specimens were collected within two months of COVID-19 diagnosis.</AbstractText><AbstractText Label="RESULTS">A total of 47 individuals were enrolled in the study, a median age of 43 years (IQR = 14.5), grouped into healthy individuals with no history of infection or exposure to SARS-CoV-2 (unexposed group; N = 21); and patients from the Health Complex of the Rio de Janeiro State University (UERJ), Brazil, who were SARS-CoV-2 positive by RT-PCR (COVID-19 group)-categorized as recovered COVID-19 (N = 11) or long-COVID-19 (N = 15). All COVID-19 patients presented at least one signal or symptom during the first two weeks of infection. Six patients were hospitalized and required invasive mechanical ventilation. Our results showed that COVID-19 patients had significantly higher levels of IFN-&#x3b3;, TNF, IL-1&#x3b2;, IL-2, IL-6, IL-8, and IP-10 than the unexposed group. The long-COVID-19 group has presented significantly high levels of IL-1&#x3b2; and IL-6 compared to unexposed individuals, but not from recovered COVID-19. A principal-component analysis demonstrated 84.3% of the total variance of inflammatory-SARS-CoV-2 response in the first two components, and it was possible to stratify IL-6, TNF, IL-1&#x3b2;, IL-10, and IL-2 as the top-five cytokines which are candidates to discriminate COVID-19 group (including long-COVID-19 subgroup) and healthy unexposed individuals.</AbstractText><AbstractText Label="CONCLUSION">We revealed important S protein-specific differential biomarkers in individuals affected by COVID-19, bringing new insights into the inflammatory status or SARS-CoV-2 exposition determination.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Gomes et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Shayane Martins Rodrigues</ForeName><Initials>SMR</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Parasitology and Immunology, Medical Science Faculty (FCM), Rio de Janeiro State University (UERJ), Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brito</LastName><ForeName>Andr&#xe9;ia Carolinne de Souza</ForeName><Initials>ACS</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Parasitology and Immunology, Medical Science Faculty (FCM), Rio de Janeiro State University (UERJ), Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfro</LastName><ForeName>W&#xe2;nia Ferraz Pereira</ForeName><Initials>WFP</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Parasitology and Immunology, Medical Science Faculty (FCM), Rio de Janeiro State University (UERJ), Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro-Alves</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Research on STD/AIDS, National Institute of Infectology Evandro Chagas, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Roberto Stefan de Almeida</ForeName><Initials>RSA</Initials><AffiliationInfo><Affiliation>Laboratory of Immunopathology, Department of General Pathology and Laboratories, FCM, UERJ, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Cal</LastName><ForeName>Mariana Soares</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0001-5537-7057</Identifier><AffiliationInfo><Affiliation>Pulmonary and Tisiology Department, Pedro Ernesto University Hospital (HUPE), Policl&#xed;nica Piquet Carneiro (PPC)/UERJ, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisboa</LastName><ForeName>Vinicius da Cunha</ForeName><Initials>VDC</Initials><AffiliationInfo><Affiliation>Laboratory of Immunopathology, Department of General Pathology and Laboratories, FCM, UERJ, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abreu</LastName><ForeName>Daniel Paiva Barros de</ForeName><Initials>DPB</Initials><AffiliationInfo><Affiliation>Chemical Engineering Program, Cell Culture Engineering Lab (COPPE), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castilho</LastName><ForeName>Leda Dos Reis</ForeName><Initials>LDR</Initials><AffiliationInfo><Affiliation>Chemical Engineering Program, Cell Culture Engineering Lab (COPPE), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porto</LastName><ForeName>Lu&#xed;s Crist&#xf3;v&#xe3;o de Moares Sobrino</ForeName><Initials>LCMS</Initials><AffiliationInfo><Affiliation>Histocompatibility and Cryopreservation Laboratory, Department of Histology and Embryology Institute of Biology Roberto Alcantara Gomes, UERJ, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mafort</LastName><ForeName>Thiago Thom&#xe1;z</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Pulmonary and Tisiology Department, Pedro Ernesto University Hospital (HUPE), Policl&#xed;nica Piquet Carneiro (PPC)/UERJ, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Agnaldo Jos&#xe9;</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0001-8598-4878</Identifier><AffiliationInfo><Affiliation>Pulmonary and Tisiology Department, Pedro Ernesto University Hospital (HUPE), Policl&#xed;nica Piquet Carneiro (PPC)/UERJ, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Silvia Amaral Gon&#xe7;alves</ForeName><Initials>SAG</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Parasitology and Immunology, Medical Science Faculty (FCM), Rio de Janeiro State University (UERJ), Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutra</LastName><ForeName>Patr&#xed;cia Maria Louren&#xe7;o</ForeName><Initials>PML</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Parasitology and Immunology, Medical Science Faculty (FCM), Rio de Janeiro State University (UERJ), Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Luciana Silva</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0003-0743-1009</Identifier><AffiliationInfo><Affiliation>Laboratory of Immunopathology, Department of General Pathology and Laboratories, FCM, UERJ, Rio de Janeiro, RJ, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054357" MajorTopicYN="N">Chemokine CXCL10</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>7</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>13</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37018291</ArticleId><ArticleId IdType="pmc">PMC10075475</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0283983</ArticleId><ArticleId IdType="pii">PONE-D-22-28458</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. COVID-19 Weekly Epidemiological Update. 2022.</Citation></Reference><Reference><Citation>Pizarro-Pennarolli C, S&#xe1;nchez-Rojas C, Torres-Castro R, Vera-Uribe R, Sanchez-Ramirez DC, Vasconcello-Castillo L, et al.. Assessment of activities of daily living in patients post COVID-19: a systematic review. PeerJ. 2021;9: e11026. doi: 10.7717/peerj.11026</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.11026</ArticleId><ArticleId IdType="pmc">PMC8034364</ArticleId><ArticleId IdType="pubmed">33868804</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al.. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19: 409&#x2013;424. doi: 10.1038/s41579-021-00573-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev E, Sarapultsev A, Solomatina L, Chereshnev V. SARS-CoV-2-specific immune response and the pathogenesis of COVID-19. Int J Mol Sci. 2022;23: 1716. doi: 10.3390/ijms23031716</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031716</ArticleId><ArticleId IdType="pmc">PMC8835786</ArticleId><ArticleId IdType="pubmed">35163638</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadotti AC, Deus M de C, Telles JP, Wind R, Goes M, Ossoski RGC, et al.. IFN-&#x3b3; is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020;289: 198171. doi: 10.1016/j.virusres.2020.198171</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2020.198171</ArticleId><ArticleId IdType="pmc">PMC7510544</ArticleId><ArticleId IdType="pubmed">32979474</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson CM, O&#x2019;Dee D, Hamilton T, Nau GJ. Cytokines Involved in Interferon-&#x3b3; Production by Human Macrophages. J Innate Immun. 2010;2: 56&#x2013;65. doi: 10.1159/000247156</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000247156</ArticleId><ArticleId IdType="pmc">PMC2943519</ArticleId><ArticleId IdType="pubmed">20375623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S, Brown HM, Hwang S. Direct Antiviral Mechanisms of Interferon-Gamma. Immune Netw. 2018;18. doi: 10.4110/in.2018.18.e33</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2018.18.e33</ArticleId><ArticleId IdType="pmc">PMC6215902</ArticleId><ArticleId IdType="pubmed">30402328</ArticleId></ArticleIdList></Reference><Reference><Citation>Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38: 1&#x2013;9. doi: 10.12932/AP-200220-0772</Citation><ArticleIdList><ArticleId IdType="doi">10.12932/AP-200220-0772</ArticleId><ArticleId IdType="pubmed">32105090</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science (1979). 2022;375: 1122&#x2013;1127. doi: 10.1126/science.abm8108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al.. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26: 845&#x2013;848. doi: 10.1038/s41591-020-0897-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0897-1</ArticleId><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al.. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591: 639&#x2013;644. doi: 10.1038/s41586-021-03207-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al.. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587: 270&#x2013;274. doi: 10.1038/s41586-020-2598-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2598-9</ArticleId><ArticleId IdType="pubmed">32726801</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al.. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181: 1489&#x2013;1501.e15. doi: 10.1016/j.cell.2020.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al.. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584: 463&#x2013;469. doi: 10.1038/s41586-020-2588-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. American Association for the Advancement of Science; 2020. pp. 473&#x2013;474. doi: 10.1126/science.abb8925</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8925</ArticleId><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al.. Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation. 2020;130: 2620&#x2013;2629. doi: 10.1172/JCI137244</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Unterman A, Sumida TS, Nouri N, Yan X, Zhao AY, Gasque V, et al.. Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nat Commun. 2022;13: 440. doi: 10.1038/s41467-021-27716-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27716-4</ArticleId><ArticleId IdType="pmc">PMC8782894</ArticleId><ArticleId IdType="pubmed">35064122</ArticleId></ArticleIdList></Reference><Reference><Citation>Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clinical Immunology. 2020;215: 108448. doi: 10.1016/j.clim.2020.108448</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108448</ArticleId><ArticleId IdType="pmc">PMC7185015</ArticleId><ArticleId IdType="pubmed">32353634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al.. COVID-19: A Multidisciplinary Review. Front Public Health. 2020;8: 1&#x2013;20. doi: 10.3389/fpubh.2020.00383</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.00383</ArticleId><ArticleId IdType="pmc">PMC7403483</ArticleId><ArticleId IdType="pubmed">32850602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes AJ, Litrento PF, Provenzano BC, Carneiro AS, Monnerat LB, da Cal MS, et al.. Small airway dysfunction on impulse oscillometry and pathological signs on lung ultrasound are frequent in post-COVID-19 patients with persistent respiratory symptoms. Milanese M, editor. PLoS One. 2021;16: 1&#x2013;14. doi: 10.1371/journal.pone.0260679</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260679</ArticleId><ArticleId IdType="pmc">PMC8629296</ArticleId><ArticleId IdType="pubmed">34843598</ArticleId></ArticleIdList></Reference><Reference><Citation>Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H, et al.. Coronavirus disease 2019 (COVID&#x2010;19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2020;93: 1&#x2013;12. doi: 10.1111/sji.12998</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12998</ArticleId><ArticleId IdType="pmc">PMC7744910</ArticleId><ArticleId IdType="pubmed">33190302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al.. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372: n693. doi: 10.1136/bmj.n693</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker-Davies RM, O&#x2019;Sullivan O, Senaratne KPP, Baker P, Cranley M, Dharm-Datta S, et al.. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020;54: 949&#x2013;959. doi: 10.1136/bjsports-2020-102596</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjsports-2020-102596</ArticleId><ArticleId IdType="pmc">PMC7418628</ArticleId><ArticleId IdType="pubmed">32475821</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudoran C, Tudoran M, Pop GN, Giurgi-Oncu C, Cut TG, Lazureanu VE, et al.. Associations between the severity of the post-acute COVID-19 syndrome and echocardiographic abnormalities in previously healthy outpatients following infection with SARS-CoV-2. Biology (Basel). 2021;10: 1&#x2013;11. doi: 10.3390/biology10060469</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology10060469</ArticleId><ArticleId IdType="pmc">PMC8226755</ArticleId><ArticleId IdType="pubmed">34073342</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan M v., McGroder C, Stevens JS, et al.. Post-acute COVID-19 syndrome. Nat Med. 2021;27: 601&#x2013;615. doi: 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J ClinPract. 2021;75. doi: 10.1111/ijcp.13746</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.13746</ArticleId><ArticleId IdType="pmc">PMC7536922</ArticleId><ArticleId IdType="pubmed">32991035</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Clinical management of COVID-19. World Health Organization. 2020. pp. 1&#x2013;62.</Citation></Reference><Reference><Citation>Alvim RGF, Lima TM, Rodrigues DAS, Marsili FF, Bozza VBT, Higa LM, et al.. From a recombinant key antigen to an accurate, affordable serological test: Lessons learnt from COVID-19 for future pandemics. BiochemEng J. 2022;186: 108537. doi: 10.1016/j.bej.2022.108537</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bej.2022.108537</ArticleId><ArticleId IdType="pmc">PMC9287463</ArticleId><ArticleId IdType="pubmed">35874089</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman H, Wang Y, Schroeder HW Jr, Cui X. Absorbance summation: A novel approach for analyzing high-throughput ELISA data in the absence of a standard. PLoS One. 2018;13: 1&#x2013;12. doi: 10.1371/journal.pone.0198528</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0198528</ArticleId><ArticleId IdType="pmc">PMC5993274</ArticleId><ArticleId IdType="pubmed">29883460</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing. 2021 [cited 17 Nov 2022]. Available: https://www.gbif.org/tool/81287/r-a-language-and-environment-for-statistical-computing</Citation></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker BM, Walker SC. Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw. 2015;67. doi: 10.18637/jss.v067.i01</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v067.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenth R v., Buerkne P, Buerkne I, Herve M, Jung M, Love J, et al. Package &#x2018;emmeans.&#x2019; 2022 [cited 2 Dec 2022]. Available: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://cran.r-project.org/web/packages/emmeans/emmeans.pdf</Citation></Reference><Reference><Citation>L&#xea; S, Josse J, Husson F. FactoMineR: An R Package for Multivariate Analysis. J Stat Softw. 2008;25: 1&#x2013;18. doi: 10.18637/jss.v025.i01</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v025.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassambara A, Mundt F. factoextra: Extract and Visualize the Results of Multivariate Data Analyses. 2020.  [cited 17 Nov 2022]. Available: https://rpkgs.datanovia.com/factoextra/index.html</Citation></Reference><Reference><Citation>Hosseini A, Hashemi V, Shomali N, Asghari F, Gharibi T, Akbari M, et al.. Innate and adaptive immune responses against coronavirus. Biomedicine &amp; Pharmacotherapy. 2020;132: 110859. doi: 10.1016/j.biopha.2020.110859</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110859</ArticleId><ArticleId IdType="pmc">PMC7580677</ArticleId><ArticleId IdType="pubmed">33120236</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al.. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern Med. 2020;180: 1081. doi: 10.1001/jamainternmed.2020.2033</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.2033</ArticleId><ArticleId IdType="pmc">PMC7218676</ArticleId><ArticleId IdType="pubmed">32396163</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain V, Yuan J-M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65: 533&#x2013;546. doi: 10.1007/s00038-020-01390-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00038-020-01390-7</ArticleId><ArticleId IdType="pmc">PMC7246302</ArticleId><ArticleId IdType="pubmed">32451563</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al.. Diabetes is a risk factor for the progression and prognosis of COVID &#x2010;19. Diabetes Metab Res Rev. 2020;36. doi: 10.1002/dmrr.3319</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3319</ArticleId><ArticleId IdType="pmc">PMC7228407</ArticleId><ArticleId IdType="pubmed">32233013</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al.. COVID&#x2010;19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020;22: 957&#x2013;966. doi: 10.1002/ejhf.1871</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1871</ArticleId><ArticleId IdType="pmc">PMC7273093</ArticleId><ArticleId IdType="pubmed">32412156</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of covid-19? BMJ. 2020;369: 1&#x2013;2. doi: 10.1136/bmj.m1548</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1548</ArticleId><ArticleId IdType="pubmed">32312785</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324: 603. doi: 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen NT, Chinn J, de Ferrante M, Kirby KA, Hohmann SF, Amin A. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. den Uil C, editor. PLoS One. 2021;16: e0254066. doi: 10.1371/journal.pone.0254066</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254066</ArticleId><ArticleId IdType="pmc">PMC8270145</ArticleId><ArticleId IdType="pubmed">34242273</ArticleId></ArticleIdList></Reference><Reference><Citation>Doerre A, Doblhammer G. The influence of gender on COVID-19 infections and mortality in Germany: Insights from age- and gender-specific modeling of contact rates, infections, and deaths in the early phase of the pandemic. Cheong SA, editor. PLoS One. 2022;17: 1&#x2013;20. doi: 10.1371/journal.pone.0268119</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0268119</ArticleId><ArticleId IdType="pmc">PMC9075634</ArticleId><ArticleId IdType="pubmed">35522614</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al.. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6: e005427. doi: 10.1136/bmjgh-2021-005427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Pel&#xe0; G, Goldoni M, Solinas E, Cavalli C, Tagliaferri S, Ranzieri S, et al.. Sex-Related Differences in Long-COVID-19 Syndrome. J Womens Health. 2022;31: 620&#x2013;630. doi: 10.1089/jwh.2021.0411</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jwh.2021.0411</ArticleId><ArticleId IdType="pubmed">35333613</ArticleId></ArticleIdList></Reference><Reference><Citation>Fathima T, Brundha MP, Ezhilarasan D. Role of Interferon Gamma in COVID-19 Prevention&#x2014;A Review. Int J Curr Res Rev. 2020;12: 91&#x2013;96. doi: 10.31782/IJCRR.2020.SP42</Citation><ArticleIdList><ArticleId IdType="doi">10.31782/IJCRR.2020.SP42</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrone L, Petruccioli E, Vanini V, Cuzzi G, NajafiFard S, Alonzi T, et al.. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clinical Microbiology and Infection. 2021;27: 286.e7&#x2013;286.e13. doi: 10.1016/j.cmi.2020.09.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.051</ArticleId><ArticleId IdType="pmc">PMC7547312</ArticleId><ArticleId IdType="pubmed">33045370</ArticleId></ArticleIdList></Reference><Reference><Citation>Murugesan K, Jagannathan P, Pham TD, Pandey S, Bonilla HF, Jacobson K, et al.. Interferon-&#x3b3; Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response. Clinical Infectious Diseases. 2021;73: e3130&#x2013;e3132. doi: 10.1093/cid/ciaa1537</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1537</ArticleId><ArticleId IdType="pmc">PMC7665338</ArticleId><ArticleId IdType="pubmed">33035306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni L, Ye F, Cheng M-L, Feng Y, Deng Y-Q, Zhao H, et al.. Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52: 971&#x2013;977.e3. doi: 10.1016/j.immuni.2020.04.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.04.023</ArticleId><ArticleId IdType="pmc">PMC7196424</ArticleId><ArticleId IdType="pubmed">32413330</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaudineau Y, Abravanel F, Izopet J, Bost C, Treiner E, Congy N, et al.. Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response. Clinical Immunology. 2022;237: 108979. doi: 10.1016/j.clim.2022.108979</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.108979</ArticleId><ArticleId IdType="pmc">PMC8920083</ArticleId><ArticleId IdType="pubmed">35301104</ArticleId></ArticleIdList></Reference><Reference><Citation>Petruccioli E, NajafiFard S, Navarra A, Petrone L, Vanini V, Cuzzi G, et al.. Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. J Transl Med. 2021;19: 272. doi: 10.1186/s12967-021-02938-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-02938-8</ArticleId><ArticleId IdType="pmc">PMC8235902</ArticleId><ArticleId IdType="pubmed">34174875</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavel AB, Glickman JW, Michels JR, Kim-Schulze S, Miller RL, Guttman-Yassky E. Th2/Th1 cytokine imbalance is associated with higher COVID-19 risk mortality. Front Genet. 2021;12. doi: 10.3389/fgene.2021.706902</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.706902</ArticleId><ArticleId IdType="pmc">PMC8324177</ArticleId><ArticleId IdType="pubmed">34335703</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordoni V, Sacchi A, Cimini E, Notari S, Grassi G, Tartaglia E, et al.. An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. Clinical Infectious Diseases. 2020;71: 2272&#x2013;2275. doi: 10.1093/cid/ciaa577</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa577</ArticleId><ArticleId IdType="pmc">PMC7239202</ArticleId><ArticleId IdType="pubmed">32407466</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID&#x2010;19: A meta-analysis. J Med Virol. 2020;92: 2283&#x2013;2285. doi: 10.1002/jmv.25948</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25948</ArticleId><ArticleId IdType="pmc">PMC7267383</ArticleId><ArticleId IdType="pubmed">32343429</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q, Zhu Z, Tan C, Zhou H, Hu Y, Shen G, et al.. Changes of serum IL-10, IL-1&#x3b2;, IL-6, MCP-1, TNF-&#x3b1;, IP-10 and IL-4 in COVID-19 patients. Int J ClinPract. 2021;75: 1&#x2013;8. doi: 10.1111/ijcp.14462</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14462</ArticleId><ArticleId IdType="pmc">PMC8237069</ArticleId><ArticleId IdType="pubmed">34107113</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell LCK, Meydan C, Kim J, Foox J, Butler D, Mason CE, et al.. Transcriptional response modules characterize IL-1&#x3b2; and IL-6 activity in COVID-19. iScience. 2021;24: 101896. doi: 10.1016/j.isci.2020.101896</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101896</ArticleId><ArticleId IdType="pmc">PMC7721347</ArticleId><ArticleId IdType="pubmed">33319166</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et BiophysicaActa. 2011. pp. 878&#x2013;888. doi: 10.1016/j.bbamcr.2011.01.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2011.01.034</ArticleId><ArticleId IdType="pubmed">21296109</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaper F, Rose-John S. Interleukin-6: Biology, signaling and strategies of blockade. Cytokine and Growth Factor Reviews. Elsevier Ltd; 2015. pp. 475&#x2013;487. doi: 10.1016/j.cytogfr.2015.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2015.07.004</ArticleId><ArticleId IdType="pubmed">26189695</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGF&#x3b2; in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24: 179&#x2013;189. doi: 10.1016/j.immuni.2006.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.01.001</ArticleId><ArticleId IdType="pubmed">16473830</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JT, Melton AC, Su G, Hamm DE, LaFemina M, Howard J, et al.. Unexpected Role for Adaptive &#x3b1;&#x3b2;Th17 Cells in Acute Respiratory Distress Syndrome. The Journal of Immunology. 2015;195: 87&#x2013;95. doi: 10.4049/jimmunol.1500054</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1500054</ArticleId><ArticleId IdType="pmc">PMC4475475</ArticleId><ArticleId IdType="pubmed">26002979</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlov M, Wander PL, Morrell ED, Mikacenic C, Wurfel MM. A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections. The Journal of Immunology. 2020;205: 892&#x2013;898. doi: 10.4049/jimmunol.2000554</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000554</ArticleId><ArticleId IdType="pmc">PMC7486691</ArticleId><ArticleId IdType="pubmed">32651218</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al.. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441: 235&#x2013;238. doi: 10.1038/nature04753</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04753</ArticleId><ArticleId IdType="pubmed">16648838</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer S, K&#xf6;stel Bal S, Egner W, Lango Allen H, Raza SI, Ma CA, et al.. Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. Journalof Experimental Medicine. 2019;216: 1986&#x2013;1998. doi: 10.1084/jem.20190344</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190344</ArticleId><ArticleId IdType="pmc">PMC6719421</ArticleId><ArticleId IdType="pubmed">31235509</ArticleId></ArticleIdList></Reference><Reference><Citation>Landi L, Ravaglia C, Russo E, Cataleta P, Fusari M, Boschi A, et al.. Blockage of interleukin-1&#x3b2; with canakinumab in patients with Covid-19. Sci Rep. 2020;10: 1&#x2013;9. doi: 10.1038/s41598-020-78492-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-78492-y</ArticleId><ArticleId IdType="pmc">PMC7733468</ArticleId><ArticleId IdType="pubmed">33311551</ArticleId></ArticleIdList></Reference><Reference><Citation>Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. Journal of Allergy and Clinical Immunology. 2020;146: 518&#x2013;534.e1. doi: 10.1016/j.jaci.2020.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7471766</ArticleId><ArticleId IdType="pubmed">32896310</ArticleId></ArticleIdList></Reference><Reference><Citation>Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. SeminImmunopathol. 2017;39: 517&#x2013;528. doi: 10.1007/s00281-017-0639-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0639-8</ArticleId><ArticleId IdType="pubmed">28555385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108: 17&#x2013;41. doi: 10.1002/JLB.3COVR0520-272R</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3COVR0520-272R</ArticleId><ArticleId IdType="pmc">PMC7323250</ArticleId><ArticleId IdType="pubmed">32534467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>